Guanhao Biotech Co

Guanhao Biotech Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Guanhao Biotech Co (300238.SZ) as of Oct 31, 2026 is 136.79 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -97.20 % — a change of -240.74% (higher).

FCF Conversion

136.79 %

YoY

-240.74%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Guanhao Biotech Co is 2025 136.79 % . FCF Conversion Rate (FCF/EBITDA) of Guanhao Biotech Co was 2024 -97.20 % . It decreases by -240.74% higher compared to the previous year.

The Guanhao Biotech Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
-3.00 CNY
Jan 1, 2019
-18.53 CNY
Jan 1, 2020
216.63 CNY
Jan 1, 2021
159.71 CNY
Jan 1, 2022
-9.68 CNY
Jan 1, 2023
0.75 CNY
Jan 1, 2024
-97.20 CNY
Jan 1, 2025
136.79 CNY
The Guanhao Biotech Co FCF Conversion history
YEARFCF ConversionYoY
136.79 %-240.74%
-97.20 %-13,138.21%
0.75 %-107.70%
-9.68 %-106.06%
159.71 %-26.28%
216.63 %-1,269.11%
-18.53 %+518.05%
-3.00 %-89.22%
-27.82 %-52.70%
-58.81 %-176.54%
76.83 %+6.82%
71.93 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Guanhao Biotech Co Stock analysis

What does Guanhao Biotech Co do? Guanhao Biotech Co Ltd develops and sells regenerative medical materials and implant devices, including biological dura mater patches, chest general surgery department patching membranes (type P and type B), asepsis biological wound-surface protection membranes, type B dura matrix, and intraocular lenses. The company generates revenue through the sale of these products to healthcare providers and medical institutions. Its primary customers are hospitals and surgical departments requiring advanced regenerative solutions for wound care and ophthalmic procedures. The firm also offers related technological services as part of its product portfolio. The company focuses on regenerative medical applications, targeting segments such as neurosurgery, general surgery, and ophthalmology. Its product range addresses specific clinical needs, including dura mater repair, wound protection, and vision correction. By providing specialized medical materials, Guanhao Biotech serves healthcare facilities seeking innovative solutions for patient recovery and surgical outcomes. Guanhao Biotech's core business revolves around the production and distribution of high-value medical devices and materials. The firm's revenue streams are derived from direct sales of its regenerative medical products and associated technological services. Key segments include hospitals, surgical departments, and ophthalmic clinics that utilize its specialized membranes and lenses for patient care. Guanhao Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Guanhao Biotech Co stock

FCF Conversion Rate (FCF/EBITDA) of Guanhao Biotech Co is 136.79 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Guanhao Biotech Co changed from -97.20 % to 136.79 %, representing a -240.74% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Guanhao Biotech Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Guanhao Biotech Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Guanhao Biotech Co

All Key Metrics — Guanhao Biotech Co